Search results
Showing 1 to 15 of 18 results for k-ras
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
NICE is unable to make a recommendation on adagrasib (Krazati) for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer in adults. This is because Bristol Myers Squibb will consider restarting this evaluation when the final overall survival analysis can be included in the economic model.
Show all sections
Sections for TA1076
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
PD-L1 50% or higher KRAS G12C positive, PD-L1 less than 50% Systemic anti-cancer therapy: treatment options for people with...
NICE is unable to recommend panitumumab with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA240
Find out which guidance and quality standards are awaiting development
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
Discontinued Reference number: GID-DT14
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.
Discontinued Reference number: GID-TA10343
Awaiting development Reference number: GID-TA11933 Expected publication date: TBC
In development Reference number: GID-TA11484 Expected publication date: TBC
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.